Individual Stock News:
1. Vanke Enterprise (02202.HK): Plans to receive a loan of no more than RMB 2.36 billion from its major shareholder, Shenzhen Metro Group; simultaneously, the extension proposals for "22 Vanke MTN005" and "22 Vanke MTN004" were approved.
2. Mingming Very Busy (01768.HK) closed up 72.44% in grey market trading.
3. China Traditional Chinese Medicine (00570.HK) issued a profit warning: It expects a net loss of approximately RMB 350 million to RMB 500 million for 2025.
4. China Overseas Property (02669.HK) issued a profit warning: It expects a 9-10% year-on-year decrease in profit attributable to shareholders for 2025.
5. Orient Securities (03958.HK): It expects a net profit attributable to shareholders of RMB 5.62 billion for 2025, an increase of 67.8% year-on-year.
6. Haitong Hengxin (01905.HK) released its 2025 preliminary financial results: annual profit of RMB 1.425 billion, a year-on-year decrease of 5.8%.
7. Shenwan Hongyuan (06806.HK) issued a profit warning: expected net profit attributable to shareholders of approximately RMB 9.1 billion to RMB 10.1 billion, a year-on-year increase of 74.64% to 93.83%.
8. Emperor Watch & Jewellery (00887.HK) issued a profit warning: expected net profit for 2025 to be no less than HKD 420 million, a year-on-year increase of over 60%.
9. CanSino Biologics (06185.HK): expected to achieve a net profit attributable to shareholders of RMB 24.5 million to RMB 29 million in 2025, turning a loss into a profit year-on-year.
10. Guotai Haitong (02611.HK) issued a profit warning: Net profit attributable to shareholders for fiscal year 2025 is expected to be approximately RMB 27.533 billion to RMB 28.006 billion, representing a year-on-year increase of 111% to 115%.
11. Fosun Pharma (02696.HK): The clinical trial application for injectable HLX43 in combination with HLX07 and Hanstig for the treatment of advanced solid tumors has been approved by the National Medical Products Administration.
12. Minmetals Resources (01208.HK): Unaudited profit for fiscal year 2025 is expected to be negatively impacted by impairment expenses (impairment amount approximately US$280 million to US$300 million before tax).
13. Simcere Pharmaceutical (02096.HK): Entered into an exclusive licensing agreement with Boehringer Ingelheim for SIM0709, under which the Group is entitled to receive an upfront payment of €42 million, and subsequent milestone payments of up to €1.016 billion.
